An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins

Apoptosis

Volumn 18, Issue 10, 2013, Pages 1175-1187

  Subramaniam, Aruljothi ^a,b   Loo, Ser Yue ^a,c   Rajendran, Peramaiyan ^a   Manu, Kanjoormana A ^a   Perumal, Ekambaram ^b   Li, Feng ^a   Shanmugam, Muthu K ^a   Siveen, Kodappully Sivaraman ^a   Park, Joo In ^d   Ahn, Kwang Seok ^e   Hui, Kam M ^f   Kumar, Alan P ^a,c,g,h   Sethi, Gautam ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b BHARATHIAR UNIVERSITY   (India)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d Dong A University College of Medicine   (South Korea)

^e Kyung Hee University   (South Korea)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g CURTIN UNIVERSITY   (Australia)

^h UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Apoptosis; CHOP; DR4; DR5; Emodin; HCC; TRAIL

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETYLCYSTEINE; CCAAT ENHANCER BINDING PROTEIN; CELL PROTEIN; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EMODIN; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EMODIN; HUMANS; LIVER NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP;

EID: 84885419305     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0851-5     Document Type: Article

References (54)

1. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448-458
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
3. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917
4. Avila MA, Berasain C, Sangro B, Prieto J (2006) New therapies for hepatocellular carcinoma. Oncogene 25:3866-3884
5. Del Pozo AC, Lopez P (2007) Management of hepatocellular carcinoma. Clin Liver Dis 11:305-321
6. Chen KF, Yeh PY, Hsu C et al (2009) Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284:11121-11133
7. Newsom-Davis T, Prieske S, Walczak H (2009) Is TRAIL the holy grail of cancer therapy? Apoptosis 14:607-623
8. Wang S (2008) The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27:6207-6215
9. Abdulghani J, El-Deiry WS (2010) TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14:1091-1108
10. Jacquemin G, Shirley S, Micheau O (2010) Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? Cell Mol Life Sci 67:3115-3130
11. Moon DO, Kim MO, Choi YH, Kim GY (2010) Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Mol Cancer Ther 9:1583-1595
12. Lalaoui N, Morle A, Merino D et al (2011) TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One 6:e19679
13. Plantivaux A, Szegezdi E, Samali A, Egan L (2009) Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? Ann NY Acad Sci 1171:38-49
14. Kim JY, Lee JY, Kim DG, Koo GB, Yu JW, Kim YS (2011) TRADD is critical for resistance to TRAIL-induced cell death through NF-kappaB activation. FEBS Lett 585:2144-2150
15. Chen KF, Chen HL, Liu CY et al (2012) Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochem Pharmacol 83:769-777
16. Lin CW, Wu CF, Hsiao NW et al (2008) Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents 32:355-359
17. Park MY, Kwon HJ, Sung MK (2009) Evaluation of aloin and aloe-emodin as anti-inflammatory agents in aloe by using murine macrophages. Biosci Biotechnol Biochem 73:828-832
18. Goel RK, Das Gupta G, Ram SN, Pandey VB (1991) Antiulcerogenic and anti-inflammatory effects of emodin, isolated from Rhamnus triquerta wall. Indian J Exp Biol 29:230-232
19. Liu YX, Shen NY, Liu C, Lv Y (2009) Immunosuppressive effects of emodin: an in vivo and in vitro study. Transpl Proc 41:1837-1839
20. Koyama J, Morita I, Tagahara K et al (2002) Chemopreventive effects of emodin and cassiamin B in mouse skin carcinogenesis. Cancer Lett 182:135-139
21. Wang SC, Zhang L, Hortobagyi GN, Hung MC (2001) Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 28:21-29
22. Su YT, Chang HL, Shyue SK, Hsu SL (2005) Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol 70:229-241
23. Chen YC, Shen SC, Lee WR et al (2002) Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 64:1713-1724
24. Wang XD, Gu LQ, Wu JY (2007) Apoptosis-inducing activity of new pyrazole emodin derivatives in human hepatocellular carcinoma HepG2 cells. Biol Pharm Bull 30:1113-1116
25. Lu HF, Lai KC, Hsu SC et al (2009) Involvement of matrix metalloproteinases on the inhibition of cells invasion and migration by emodin in human neuroblastoma SH-SY5Y cells. Neurochem Res 34:1575-1583
26. Shieh DE, Chen YY, Yen MH, Chiang LC, Lin CC (2004) Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci 74:2279-2290
27. Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G, Pinna LA (2000) The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem 275:29618-29622
28. Kumar A, Dhawan S, Aggarwal BB (1998) Emodin (3-methyl-1,6,8- trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene 17:913-918
29. Huang Q, Shen HM, Ong CN (2004) Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 68:361-371
30. Brown M, Bellon M, Nicot C (2007) Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 109:1653-1659
31. Suboj P, Babykutty S, Valiyaparambil Gopi DR, Nair RS, Srinivas P, Gopala S (2012) Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-kappaB. Eur J Pharm Sci 45:581-591
32. Manu KA, Shanmugam MK, Ong TH et al (2013) Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. PLoS One 8:e57015
33. Cho YW, Hong T, Hong S et al (2007) PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J Biol Chem 282:20395-20406
34. Rajendran P, Ong TH, Chen L et al (2011) Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 17:1425-1439
35. Yoshida T, Shiraishi T, Nakata S et al (2005) Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65:5662-5667
36. Kim H, Kim EH, Eom YW et al (2006) Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 66:1740-1750
37. Yamanaka T, Shiraki K, Sugimoto K et al (2000) Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32:482-490
38. Zhang L, Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237
39. Dzieran J, Beck JF, Sonnemann J (2008) Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci 99:1685-1692
40. Pellerito O, Calvaruso G, Portanova P et al (2010) The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Mol Pharmacol 77:854-863
41. Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB (2009) Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res 69:6581-6589
42. Kim HR, Kim K, Lee KH, Kim SJ, Kim J (2008) Inhibition of casein kinase 2 enhances the death ligand- and natural kiler cell-induced hepatocellular carcinoma cell death. Clin Exp Immunol 152:336-344
43. Wang S (2010) TRAIL: a sword for killing tumors. Curr Med Chem 17:3309-3317
44. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O (2006) Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26:7046-7055
45. Irmler M, Thome M, Hahne M et al (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195
46. Kim YH, Jung EM, Lee TJ et al (2008) Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 44:1055-1068
47. Mellier G, Huang S, Shenoy K, Pervaiz S (2010) TRAILing death in cancer. Mol Aspects Med 31:93-112
48. Nikolovska-Coleska Z, Xu L, Hu Z et al (2004) Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47:2430-2440
49. Naumann U, Bahr O, Wolburg H et al (2007) Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Ther 14:147-161
50. Sethi G, Tergaonkar V (2009) Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol Sci 30:313-321
51. Ravi R, Bedi A (2002) Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res 62:1583-1587
52. Jacobson MD (1996) Reactive oxygen species and programmed cell death. Trends Biochem Sci 21:83-86
53. Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK (2005) Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26:1905-1913
54. Moon DO, Park SY, Choi YH, Ahn JS, Kim GY (2011) Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: involvement of ROS-dependent ER-stress. Biochem Pharmacol 82:1641-1650